SOX12 is a transcriptional activator that plays critical roles in cancer progression and immune regulation. In hepatocellular carcinoma, SOX12 promotes immunosuppression by transcriptionally activating CCL22 to recruit regulatory T-cells and upregulating CD274 (PD-L1) to suppress CD8+ T-cell infiltration, ultimately facilitating tumor metastasis 1. The protein functions as an oncogene across multiple cancer types, including breast cancer where its expression correlates with tumor progression, lymph node metastasis, and poor overall survival 2. In thyroid cancer, SOX12 promotes proliferation and invasion by regulating POU2F1 and POU3F1 expression 3, while in endometrial cancer, it directly binds to and activates PHGDH transcription, enhancing serine synthesis pathways that contribute to tumor metabolism and progression 4. SOX12 also maintains cancer stemness, as demonstrated in gastric cancer where it acts downstream of FOXP4 in the YAP1 signaling pathway 5. Beyond cancer, SOX12 functions redundantly with other SOXC family members to regulate adult bone mass by controlling osteoblast and osteoclast differentiation 6. In acute myeloid leukemia, SOX12 knockdown induces apoptosis through caspase activation 7.